RU2008103608A - Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела - Google Patents
Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела Download PDFInfo
- Publication number
- RU2008103608A RU2008103608A RU2008103608/15A RU2008103608A RU2008103608A RU 2008103608 A RU2008103608 A RU 2008103608A RU 2008103608/15 A RU2008103608/15 A RU 2008103608/15A RU 2008103608 A RU2008103608 A RU 2008103608A RU 2008103608 A RU2008103608 A RU 2008103608A
- Authority
- RU
- Russia
- Prior art keywords
- therapeutic antibody
- target antigen
- sample
- antibody
- complex
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract 26
- 239000000427 antigen Substances 0.000 title claims abstract 17
- 102000036639 antigens Human genes 0.000 title claims abstract 17
- 108091007433 antigens Proteins 0.000 title claims abstract 17
- 238000000034 method Methods 0.000 claims abstract 21
- 238000003018 immunoassay Methods 0.000 claims abstract 6
- 230000015572 biosynthetic process Effects 0.000 claims abstract 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims abstract 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract 2
- 229940120638 avastin Drugs 0.000 claims abstract 2
- 229940022353 herceptin Drugs 0.000 claims abstract 2
- 229960004641 rituximab Drugs 0.000 claims abstract 2
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05014618 | 2005-07-06 | ||
EP05014618.2 | 2005-07-06 | ||
EP06004447.6 | 2006-03-06 | ||
EP06004447 | 2006-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2008103608A true RU2008103608A (ru) | 2009-08-20 |
Family
ID=36922121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008103608/15A RU2008103608A (ru) | 2005-07-06 | 2006-07-05 | Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела |
Country Status (19)
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0111355A (pt) * | 2000-05-19 | 2003-04-29 | Genentech Inc | Método para o aumento da probabilidade de eficácia de um tratamento contra o câncer com antagonistas de erbb, método para o aumento da probabilidade de eficácia de um anticorpo anti-her2 no tratamento de câncer, embalagem farmacêutica, método para a identificação de um paciente disposto a responder favoravelmente a um antagonista de erbb para o tratamento de câncer e usos |
KR20180091967A (ko) | 2004-07-22 | 2018-08-16 | 제넨테크, 인크. | Her2 항체 조성물 |
WO2006039486A2 (en) | 2004-10-01 | 2006-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Imaging arrangements and methods therefor |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
AU2006216732C1 (en) | 2005-02-23 | 2017-07-20 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US8358354B2 (en) | 2009-01-26 | 2013-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Correction of optical abberations |
WO2007092581A2 (en) | 2006-02-07 | 2007-08-16 | The Board Of Trustees Of The Leland Stanford Junior University | Correction of optical aberrations |
KR20150039212A (ko) | 2007-03-02 | 2015-04-09 | 제넨테크, 인크. | 낮은 her3 발현을 기초로 한 her 이량체화 억제제에 대한 반응 예측 |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
SI4241849T1 (sl) | 2011-10-14 | 2025-01-31 | F. Hoffmann-La Roche Ag | Načini uporabe in proizvodni izdelek, vključno s pertuzumabom - zaviralcem dimerizacije receptorja HER2 |
KR101327542B1 (ko) * | 2012-03-15 | 2013-11-08 | 광주과학기술원 | 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법 |
AU2012232949B2 (en) * | 2012-09-28 | 2014-07-03 | Willowtree Holdings Pty Ltd | Temporary bulkhead |
NZ751877A (en) | 2013-04-16 | 2020-04-24 | Genentech Inc | Pertuzumab variants and evaluation thereof |
JP2017513901A (ja) | 2014-04-25 | 2017-06-01 | ジェネンテック, インコーポレイテッド | トラスツズマブ−mcc−dm1及びペルツズマブにより早期の乳癌を処置する方法 |
JP6822980B2 (ja) | 2015-05-30 | 2021-01-27 | ジェネンテック, インコーポレイテッド | Her2陽性転移性乳癌の治療方法 |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
JP6914336B2 (ja) | 2016-12-28 | 2021-08-04 | ジェネンテック, インコーポレイテッド | 進行したher2発現がんの治療 |
KR20200113292A (ko) | 2017-01-17 | 2020-10-06 | 제넨테크, 인크. | 피하 her2 항체 제형 |
IL289297B2 (en) | 2017-03-02 | 2023-09-01 | Hoffmann La Roche | Adjuvant treatment for her2-positive breast cancer |
EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2095818B (en) | 1981-03-27 | 1985-10-02 | Exxon Research Engineering Co | Staged adsorption/resorption heat pump |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
ATE255131T1 (de) * | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
EP0931147A1 (en) | 1996-10-18 | 1999-07-28 | Genentech, Inc. | ANTI-ErbB2 ANTIBODIES |
EP1438583B1 (en) * | 2001-09-20 | 2009-09-16 | Board of Regents, The University of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays |
HUP0600340A3 (en) * | 2002-07-15 | 2011-06-28 | Genentech Inc | Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies |
-
2006
- 2006-06-29 MY MYPI20063118A patent/MY157955A/en unknown
- 2006-06-29 US US11/477,772 patent/US20070009976A1/en not_active Abandoned
- 2006-07-04 TW TW095124248A patent/TWI312864B/zh active
- 2006-07-04 AR ARP060102872A patent/AR053948A1/es not_active Application Discontinuation
- 2006-07-05 NZ NZ564471A patent/NZ564471A/en unknown
- 2006-07-05 RU RU2008103608/15A patent/RU2008103608A/ru unknown
- 2006-07-05 MX MX2008000277A patent/MX2008000277A/es not_active Application Discontinuation
- 2006-07-05 EP EP10157725A patent/EP2194380A3/en not_active Withdrawn
- 2006-07-05 EP EP06754671A patent/EP1902315A1/en not_active Withdrawn
- 2006-07-05 AU AU2006265275A patent/AU2006265275A1/en not_active Abandoned
- 2006-07-05 CA CA002613187A patent/CA2613187A1/en not_active Abandoned
- 2006-07-05 WO PCT/EP2006/006524 patent/WO2007003420A1/en active Application Filing
- 2006-07-05 BR BRPI0612591-3A patent/BRPI0612591A2/pt not_active IP Right Cessation
- 2006-07-05 KR KR1020087000259A patent/KR20080016939A/ko not_active Ceased
- 2006-07-05 JP JP2008519853A patent/JP2008545145A/ja active Pending
-
2007
- 2007-12-20 IL IL188317A patent/IL188317A0/en unknown
- 2007-12-21 CR CR9635A patent/CR9635A/es not_active Application Discontinuation
- 2007-12-28 NO NO20076662A patent/NO20076662L/no not_active Application Discontinuation
-
2008
- 2008-01-04 EC EC2008008081A patent/ECSP088081A/es unknown
- 2008-02-01 MA MA30617A patent/MA29730B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2008545145A (ja) | 2008-12-11 |
MX2008000277A (es) | 2008-03-24 |
AR053948A1 (es) | 2007-05-23 |
MY157955A (en) | 2016-08-30 |
AU2006265275A1 (en) | 2007-01-11 |
TWI312864B (en) | 2009-08-01 |
EP1902315A1 (en) | 2008-03-26 |
TW200741203A (en) | 2007-11-01 |
US20070009976A1 (en) | 2007-01-11 |
WO2007003420A1 (en) | 2007-01-11 |
NZ564471A (en) | 2010-04-30 |
BRPI0612591A2 (pt) | 2010-11-23 |
ECSP088081A (es) | 2008-02-20 |
CR9635A (es) | 2008-02-20 |
MA29730B1 (fr) | 2008-09-01 |
EP2194380A3 (en) | 2010-07-14 |
IL188317A0 (en) | 2008-04-13 |
NO20076662L (no) | 2008-04-03 |
KR20080016939A (ko) | 2008-02-22 |
CA2613187A1 (en) | 2007-01-11 |
EP2194380A2 (en) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2008103608A (ru) | Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела | |
JP2008545145A5 (enrdf_load_stackoverflow) | ||
CY1112631T1 (el) | ΜΕΘΟΔΟΙ ΤΑΥΤΟΠΟΙΗΣΗΣ ΟΓΚΩΝ ΠΟΥ ΑΠΟΚΡΙΝΟΝΤΑΙ ΣΕ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΕrbB2 | |
CA2749846A1 (en) | Methods of determining patient response by measurement of her-3 | |
CN110383068A (zh) | 评估患者样品中uch-l1状态的改进方法 | |
DE50306067D1 (de) | Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern | |
DK1668368T3 (da) | Detektion af histon-modifikation i cellefrie nukleosomer | |
WO2018175942A1 (en) | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 | |
WO2010038974A3 (ko) | 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트 | |
FR2933773B1 (fr) | Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal | |
RU2014103054A (ru) | Применение антитела i-3859 для выявления и диагностики рака | |
JP4608432B2 (ja) | 腫瘍マーカーとしてのn▲1▼,n▲12▼−ジアセチルスペルミン | |
US20150198598A1 (en) | Kit for diagnosing malignant melanoma | |
FI3356826T3 (fi) | Gdf-15 melanooman diagnostisena markkerina | |
US11242408B2 (en) | Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis | |
ATE532796T1 (de) | Immunassays zur spezifischen bestimmung von scca- isoformen | |
KR20240139074A (ko) | 샘플에서 유비퀴틴 카르복시-말단 히드롤라제 l1 및/또는 신경교 섬유성 산성 단백질의 존재를 검출하거나 또는 그의 양을 측정하기 위한 측면 유동 방법, 검정 및 기기 | |
EP3602069A1 (en) | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 | |
AU2022339759A1 (en) | Methods and systems of diagnosing brain injury | |
ATE493662T1 (de) | Diagnostischer test für menschliches matrix gla- protein und seine verwendung als biomarker | |
EA202090834A1 (ru) | Набор реагентов для выявления маркера эпителиальных карцином | |
WO2024040238A3 (en) | Method of diagnosing and treating prostate cancer using zinc finger protein-like 1 antibodies | |
CA3240822A1 (en) | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples | |
WO2025010375A3 (en) | Anti-grp78 antibodies and their uses | |
WO2006060188A3 (en) | Anti-tenascin monoclonal antibody immunoassays and diagnostic kits |